Prognostic value of the 2002 TNM classification for breast carcinoma with regard to the number of metastatic axillary lymph nodes

Cancer

Volumn 104, Issue 4, 2005, Pages 700-707

  Duraker, Nüvit ^a,b   Çaynak, Zeynep Civelek ^a  

^a OKMEYDANI EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b NONE   (Turkey)

Author keywords

Breast carcinoma; Lymph node classification; Prognosis; Stage IIIC disease; TNM staging

Indexed keywords

ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER STAGING; CANCER SURVIVAL; CLINICAL PROTOCOL; DISEASE CLASSIFICATION; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS;

BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHATIC METASTASIS; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 23444445840     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21199     Document Type: Article

References (23)

1. Beahrs OH, Henson DE, Hutter RVP, Myers M, editors. American Joint Committee on Cancer. Manual for staging of cancer, 3rd ed. Philadelphia: J.B. Lippincott, 1987.
2. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ, editors. American Joint Committee on Cancer. Manual for staging of cancer, 4th ed. Philadelphia: J.B. Lippincott, 1992.
3. Fleming ID, Cooper JS, Henson DE, et al., editors. AJCC cancer staging manual, 5th ed. Philadelphia: Lippincott-Raven, 1997.
4. Sobin LH. TNM: principles, history and relation to other prognostic factors. Cancer. 2001;91:1589-1592.
5. Greene FL, Page DL, Fleming ID, et al., editors. AJCC cancer staging manual, 6th ed. New York: Springer-Verlag, 2002.
6. Nemoto T, Vana J, Bedwani RN, Baker HW, McGregor FH, Murphy GP. Management and survival of female breast cancer: results of a national survey by the American College of Surgeons. Cancer. 1980;45:2917-2924.
7. Fisher B, Bauer M, Wickerham DL, et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer: an NSABP update. Cancer. 1983;52: 1551-1557.
8. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63:181-187.
9. Rosen PP, Groshen S, Saigo PE, Kinne DW, Hellman S. A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. J Clin Oncol. 1989; 7:355-366.
10. Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med. 1997;337:949-955.
11. Senn HJ, Maibach R, Castiglione M, et al. Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil-11-year results of Swiss Group for Clinical Cancer Research Trial SAKK 27/82. J Clin Oncol. 1997;15:2502-2509.
12. Overgaard M, Jensen M-B, Overgaard J, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet. 1999;353:1641-1648.
13. Pisansky TM, Ingle JN, Schaid DJ, et al. Patterns of tumor relapse following mastectomy and adjuvant systemic therapy in patients with axillary lymph node-positive breast cancer: impact of clinical, histopathologic, and flow cytometric factors. Cancer. 1993;72:1247-1260.
14. Saarto T, Blomqvist C, Välimäki M, Mäkelä P, Sarna S, Elomaa I. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol. 1997;15:1341-1347.
15. Levine MN, Bramwell VH, Pritchard KI, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. J Clin Oncol. 1998;16:2651-2658.
16. Fisher ER, Anderson S, Redmond C, Fisher B. Pathologic findings from the National Surgical Adjuvant Breast Project Protocol B-06: 10-year pathologic and clinical prognostic discriminants. Cancer. 1993;71:2507-2514.
17. De Laurentiis M, Gallo C, De Placido S, et al. A predictive index of axillary nodal involvement in operable breast cancer. Br J Cancer. 1996;73:1241-1247.
18. Fisher B, Anderson S, Wickerham DL, et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol. 1997; 15:1858-1869.
19. Antman KH, Rowlings PA, Vaughan WP, et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol. 1997;15:1870-1879.
20. Gianni AM, Siena S, Bregni M, et al. Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results. J Clin Oncol. 1997; 15:2312-2321.
21. Singletary SE, Allred C, Ashley P, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 2002;20:3628-3636.
22. Woodward WA, Strom EA, Tucker SL, et al. Changes in the 2003 American Joint Committee on Cancer staging for breast cancer dramatically affect stage-specific survival. J Clin Oncol. 2003;21:3244-3248.
23. Gospodarowicz MK, Miller D, Groome PA, Greene FL, Logan PA, Sobin LH. The process for continuous improvement of the TNM classification. Cancer. 2004;100:1-5.